LTRN - Latest News
Lantern Pharma Inc. (LTRN), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $28.4M. Beta to the broader market is 2.10.
The article list below shows the most recent LTRN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent LTRN Headlines
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
businesswire.com - May 15, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates.
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
businesswire.com - May 14, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $9.
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
businesswire.com - May 13, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces up to $9.
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
businesswire.com - May 11, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026.
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
businesswire.com - May 7, 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of
How News Affects LTRN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track LTRN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked LTRN news questions
- What is the latest LTRN news headline?
- The most recent LTRN headline (May 15, 2026) is "Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the LTRN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What LTRN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual LTRN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.